- Home
- AGX vs TARS Comparison
AGX vs TARS Comparison
Compare AGX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGX
- TARS
- Stock Information
- Founded
- AGX 1961
- TARS 2016
- Country
- AGX United States
- TARS United States
- Employees
- AGX N/A
- TARS N/A
- Industry
- AGX Engineering & Construction
- TARS Medicinal Chemicals and Botanical Products
- Sector
- AGX Consumer Discretionary
- TARS Health Care
- Exchange
- AGX Nasdaq
- TARS Nasdaq
- Market Cap
- AGX 2.1B
- TARS 2.1B
- IPO Year
- AGX N/A
- TARS 2020
- Fundamental
- Price
- AGX $167.87
- TARS $44.33
- Analyst Decision
- AGX Buy
- TARS Strong Buy
- Analyst Count
- AGX 3
- TARS 5
- Target Price
- AGX $123.33
- TARS $54.20
- AVG Volume (30 Days)
- AGX 298.1K
- TARS 706.2K
- Earning Date
- AGX 12-05-2024
- TARS 02-25-2025
- Dividend Yield
- AGX 0.90%
- TARS N/A
- EPS Growth
- AGX 92.83
- TARS N/A
- EPS
- AGX 4.81
- TARS N/A
- Revenue
- AGX $806,259,000.00
- TARS $129,621,000.00
- Revenue This Year
- AGX $47.84
- TARS $917.88
- Revenue Next Year
- AGX $6.90
- TARS $78.70
- P/E Ratio
- AGX $34.96
- TARS N/A
- Revenue Growth
- AGX 52.83
- TARS 801.96
- 52 Week Low
- AGX $43.44
- TARS $20.08
- 52 Week High
- AGX $176.85
- TARS $57.14
- Technical
- Relative Strength Index (RSI)
- AGX 66.74
- TARS 28.56
- Support Level
- AGX $151.17
- TARS $52.69
- Resistance Level
- AGX $160.44
- TARS $57.00
- Average True Range (ATR)
- AGX 7.72
- TARS 2.71
- MACD
- AGX 2.28
- TARS -1.28
- Stochastic Oscillator
- AGX 78.09
- TARS 5.32
About AGX Argan Inc.
Argan Inc is a United States-base construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derive majority revenue.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.